FMR1 and fragile X syndrome: (xi) CRISPR–gold targeting the metabotropic glutamate receptor 5 (mGluR5) gene efficiently reduced local mGluR5 protein levels in the striatum by 40–50% following intracranial injection into the brains of Fmr1 knockout mice, a model of fragile X syndrome (FXS).